# Edgewise Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Edgewise Therapeutics, Inc.). ## Overview Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for rare neuromuscular and cardiomyopathy diseases. Its pipeline is centered on small-molecule drug candidates such as sevasemten and EDG-7500, which are being advanced through Phase 2 trials and preclinical development. ## Products & services • Sevasemten for muscular dystrophy programs • EDG-7500 for hypertrophic cardiomyopathy (HCM) • EDG-003 cardiometabolic discovery program • Proprietary small-molecule drug discovery platform • Preclinical and clinical development services for its pipeline - **Sevasemten program** (55%) — Clinical-stage small-molecule therapy for rare neuromuscular diseases, including Becker and other muscular dystrophies. - **EDG-7500 program** (25%) — Clinical-stage candidate being developed for hypertrophic cardiomyopathy. - **Discovery pipeline** (10%) — Earlier-stage cardiometabolic programs, including EDG-003 and additional candidates. - **Drug discovery platform** (10%) — Internal platform used to identify and optimize small-molecule precision medicines. - Sevasemten for Becker, Duchenne and LGMD-related muscle disease - EDG-7500 for hypertrophic cardiomyopathy (HCM) - EDG-003 cardiometabolic discovery program - Proprietary small-molecule drug discovery platform - Preclinical and Phase 2 clinical development programs ## Customers Edgewise does not yet sell approved products; its current 'customers' are clinical trial participants, investigators, CROs, CDMOs, and regulators that enable development. If approved, its commercial buyers would be specialty physicians, hospitals, and payors covering rare-disease and cardiology therapies in the U.S. and select international markets. - **Rare neuromuscular disease patients** (primary) — Patients with Becker, Duchenne and related muscular dystrophies who would use sevasemten if approved. - **Hypertrophic cardiomyopathy patients** (primary) — Patients with HCM targeted by EDG-7500 clinical development and eventual commercialization. - **Clinical trial ecosystem** (secondary) — Investigators, CROs and sites that execute the company's Phase 2 studies and generate development data. - **CDMO and manufacturing partners** (secondary) — Third-party manufacturers that supply active ingredient and fill-finish services for preclinical and clinical material. - **Future payors and specialty prescribers** (emerging) — Government and commercial payors, plus specialists, that would determine access and uptake after approval. - Patients with Becker, Duchenne, LGMD and other rare muscle diseases - Patients with hypertrophic cardiomyopathy enrolled in clinical trials - Clinical investigators and trial sites running Phase 2 studies - CROs and CDMOs supporting development and manufacturing - Future payors and specialty providers if products reach market ## Geography Edgewise is headquartered in Boulder, Colorado and currently conducts development primarily in the United States. Management says any approved products would be marketed in the U.S. and select international markets, which makes future reimbursement and pricing exposure meaningfully global even though the company is still pre-commercial. - Headquartered in Boulder, Colorado, United States - Clinical development is primarily U.S.-based today - Plans to commercialize in the U.S. and select international markets - International reimbursement systems may constrain pricing and access - Manufacturing is outsourced to CDMOs rather than owned plants ## Strategy Edgewise is prioritizing advancement of sevasemten and EDG-7500 through Phase 2 development while building the data package needed for regulatory discussions and future commercialization. It is also expanding its discovery platform and operational infrastructure so it can support later-stage trials, manufacturing redundancy, and eventual market launch. - **Complete and read out Phase 2 sevasemten studies** (short-term) — Clinical data in Becker and other muscular dystrophies is central to regulatory and partnering value. - **Advance EDG-7500 in HCM** (short-term) — Diversifies the pipeline into cardiology and broadens the company's future commercial opportunity. - **Prepare for commercialization and reimbursement** (medium-term) — Rare-disease drugs depend on payer coverage and pricing discipline to be commercially viable. - **Expand discovery and manufacturing resilience** (medium-term) — Additional candidates and redundant supply reduce single-asset and single-source risk. - Advance sevasemten through multiple Phase 2 muscular dystrophy trials - Progress EDG-7500 in the CIRRUS-HCM Phase 2 program - Develop additional cardiometabolic candidates from EDG-003 - Build regulatory and commercial readiness before approval - Add manufacturing redundancy and qualify additional CDMOs ## Risks Edgewise is a pre-revenue clinical-stage company, so its value depends heavily on successful trial outcomes, regulatory approval, and future reimbursement. It also relies on third-party CROs and CDMOs for development and manufacturing, which creates execution and supply-chain risk, while rare-disease pricing and payor coverage could limit commercialization even if approval is achieved. - **Clinical development failure** [critical] — Sevasemten and EDG-7500 are still in Phase 2, and efficacy or safety issues could halt programs. - **Regulatory approval uncertainty** [high] — FDA and ex-U.S. regulators may require additional data or reject applications for rare-disease indications. - **Reimbursement and pricing risk** [high] — Small patient populations require high per-patient pricing, but payors may restrict coverage or reimbursement levels. - **Third-party manufacturing dependence** [high] — The company uses CDMOs on purchase-order terms and lacks redundant supply arrangements today. - **Capital needs and dilution** [high] — As a pre-revenue biotech, continued R&D and trial expansion may require additional financing. - No approved products yet, so value depends on clinical success - Phase 2 data may fail to support approval or partnering - Reimbursement and pricing pressure could limit rare-disease uptake - Dependence on CROs and CDMOs creates execution and supply risk - Need for additional capital remains if development timelines slip ## Accounting The most important accounting judgments are accrued R&D expenses, which depend on estimating services performed by CROs, investigators and CDMOs before invoices arrive. Because the company is pre-revenue and heavily trial-driven, period-to-period expense recognition can be uneven, and stock-based compensation, cash burn, and any future fair-value or impairment judgments will also matter to investors. - **Accrued research and development expenses** — Can shift expenses between periods and affect operating loss comparability - **Clinical trial and manufacturing accruals** — Quarterly R&D expense volatility - **Stock-based compensation** — Raises operating expenses without immediate cash outflow - **Liquidity and going-concern assessment** — Affects investor view of dilution and funding risk - Accrued R&D estimates affect reported trial and manufacturing costs - CRO and CDMO milestone billing can create uneven quarterly expense timing - Stock-based compensation is a meaningful operating expense for a biotech - No product revenue yet, so future revenue recognition will be event-driven - Cash, marketable securities and financing history affect going-concern analysis --- *Last updated: 2026-04-28T20:04:22.154358+00:00*